A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis

Официальное название

An Open-Label, Positive Drug-Controlled, Parallel, Multicenter Phase II Clinical Trial of the Efficacy, Safety, and Pharmacokinetics of Flonoltinib Maleate Tablets in Patients With Intermediate to High-Risk Myelofibrosis

Обзор

This trial adopts a multicenter, open-label, positive drug parallel control clinical trial design, planning to enroll approximately 75 MF participants. Eligible participants will be stratified and assigned in a 1:1:1 ratio to the low-dose flonoltinib maleate tablet group, high-dose flonoltinib maleate tablet group, or the ruxolitinib tablet group. Stratification factor include the Dynamic International Prognostic Scoring System (DIPSS) risk classification (intermediate-2 and high risk)

Вмешательства

• Препарат Flonoltinib 50mg
  Flonoltinib 50mg, QD
• Препарат Flonoltinib 100mg
  Flonoltinib 100mg, QD
• Препарат Ruxolitinib
  For patients with platelet counts between 100×10\^9/L and 200×10\^9/L, the recommended starting dose is 15 mg twice daily (bid). For patients with platelet counts \>200×10\^9/L, the recommended starting dose is 20 mg bid. For patients with platelet counts between 50×10\^9/L and \<100×10\^9/L, the recommended maximum starting dose is 5 mg bid.

Первичные конечные точки

• Percentage of subjects with ≥35% reduction in spleen volume from baseline(Evaluation by IRC) [Срок оценки: Week 24]

Вторичные конечные точки (5)

• Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by researcher) [Срок оценки: Week 24]
• Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by researcher) [Срок оценки: Week 12]
• Percentage of subjects with ≥35% reduction in spleen volume from baseline (Evaluation by IRC) [Срок оценки: Week 12]
• Percentage of subjects with ≥50% reduction in MPN-SAF TSS scale total symptom score [Срок оценки: Week 24 and Week 12]
• Objective response rate (ORR = CR + PR) per the IWG-MRT consensus criteria. [Срок оценки: Week 24]

Критерии участия

Критерии включения

• Age ≥ 18 years, no gender restrictions;
• Diagnosed with primary myelofibrosis (PMF) according to WHO criteria (2016 edition) or post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF) according to IWG-MRT criteria;
• Evaluated as intermediate-2 or high-risk myelofibrosis according to the Dynamic International Prognostic Scoring System (DIPSS) risk classification;
• Expected survival ≥ 24 weeks;
• ECOG score of 0-2;
• Splenomegaly: palpable spleen edge reaching or exceeding 5 cm below the costal margin (distance from the intersection of the left midclavicular line and the left costal margin to the farthest point of the spleen); or not palpable due to body habitus (obesity) but confirmed by magnetic resonance imaging (MRI ) (or CT scan if necessary) at screening with spleen volume ≥ 450 cm³;
• Blasts in peripheral blood and bone marrow ≤ 10%; 8) Within 7 days before the first dose, absolute absolute neutrophil count (ANC )≥ 1.0×10\^9/L, platelet count ≥ 50×10\^9/L, hemoglobin (HGB )> 60 g/L (participants should not have received growth factors, colony-stimulating factors, thrombopoietic agents, or platelet transfusions within 2 weeks before the baseline assessment prior to the first dose); 9) Major organ function basically normal within 7 days before the first dose; 10) Able to understand and voluntarily sign the informed consent form.

Критерии исключения

• Previous anticancer treatment-related toxic reactions have not recovered to grade 1 or below (excluding alopecia and conditions specified in inclusion criteria 8 and 9), or have not fully recovered from previous surgery (major surgery within 4 weeks);
• Hypersensitivity, allergic to the investigational drug or its excipients;
• Previous intolerance or resistance to ruxolitinib;
• Use of JAK inhibitors within 4 weeks before the first dose;
• Any significant clinical and laboratory abnormalities that, in the investigator's opinion, affect safety evaluation;
• History of congestive heart failure, unstable angina, myocardial infarction, cerebrovascular accident (excluding lacunar infarction), or pulmonary embolism within 6 months prior to screening;
• Impaired cardiac function or arrhythmic disease requiring treatment at screening;
• Any active infection requiring intravenous antibiotic treatment at screening;
• Active tuberculosis infection within 48 weeks prior to screening or latent tuberculosis infection indicated by tuberculosis-related tests during the screening period;
• Patients who have undergone splenectomy or received radiation therapy to the spleen area within 12 months before the first dose;
• Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, except for: a) HBV infection: Patients with positive hepatitis B surface antigen (HbsAg) or hepatitis B core antibody (HbcAb) with undetectable peripheral blood HBV-DNA (below the detection limit of the testing laboratory) can be enrolled; they must continue antiviral therapy and have HBV-DNA testing every 12 weeks and at the end of treatment (EOT); b) HCV seropositive patients with negative HCV RNA can be enrolled.
• Positive for human immunodeficiency virus antibody (HIV-Ab) or Treponema pallidum antibody (TP-Ab) (patients with positive Treponema pallidum antibody can have a titer test, and the investigator will determine eligibility based on comprehensive judgment);
• Patients with epilepsy or those using psychiatric drugs or sedatives at screening (excluding those used for sleep purposes);
• Pregnant or breastfeeding women, and patients with reproductive potential (male and female) who refuse to use contraceptive measures during the trial and for 6 months after the trial;
• Patients who have had another malignancy within 5 years before the first dose (excluding cured in-situ carcinoma and basal cell carcinoma of the skin);
• Patients with other severe diseases that, in the investigator's opinion, may affect safety or compliance;
• Patients who participated in other clinical trials of investigational drugs or medical devices within 1 month before the first dose and used the investigational drug or device;
• Use of any treatment for MF (other than JAK inhibitors) within 2 weeks or 5 half-lives (whichever is longer) before the first dose, any immunomodulatory agents (e.g., thalidomide), any immunosuppressants, ≥10 mg/day prednisone or equivalent biological potency corticosteroids, or growth factors (e.g., erythropoietin (EPO)) (Traditional Chinese medicine should be stopped 1 day before the first dose);
• Patients with a history of congenital or acquired bleeding disorders;
• Other factors that the investigator deems unsuitable for participation in the trial.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 2 центра

• West China Hospital Sichuan University — Чэнду
• Hematology Hospital, Chinese Academy of Medical Sciences — Тяньцзинь

Публикации

• Yang L, Tan K, Liang R, Zhang W, Wang Y, Chen L. Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial. Ther Adv Hematol. 2026 Mar 19;17:20406207261424845. doi: 10.1177/20406207261424845. eCollection 2026. PMID 41883618

Идентификаторы

NCT: NCT06457425 · FMF-02

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗